Clinical trial
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial
NCT02964195 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- November 30, 2016
- Completion date
- April 30, 2018
- Enrollment
- 308 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.